Blueprint Medicines to Present at Upcoming Investor Conferences

Rhea-AI Summary

Blueprint Medicines (NASDAQ: BPMC) has announced its participation in two upcoming virtual investor conferences. The company will present at the Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET, and at TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.

Investors and interested parties can access live webcasts of both presentations through the Investors & Media section of Blueprint Medicines' website. Replays of the webcasts will be available on the company's website for 30 days following each presentation, providing an opportunity for those unable to attend the live events to catch up on the information shared.

CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences:

• Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET.
• TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.

A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT^®/AYVAKYT^® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-302232128.html

SOURCE Blueprint Medicines Corporation

FAQ

When is Blueprint Medicines (BPMC) presenting at the Stifel 2024 Immunology and Inflammation Virtual Summit?

Blueprint Medicines (BPMC) is presenting at the Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET.

What time is Blueprint Medicines (BPMC) presenting at TD Cowen's Chronic Urticaria Summit?

Blueprint Medicines (BPMC) is presenting at TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.

How can investors access Blueprint Medicines' (BPMC) presentations at the upcoming conferences?

Investors can access live webcasts of Blueprint Medicines' (BPMC) presentations through the Investors & Media section of the company's website at http://ir.blueprintmedicines.com.

How long will replays of Blueprint Medicines' (BPMC) conference presentations be available?

Replays of Blueprint Medicines' (BPMC) conference presentations will be archived on the company's website for 30 days following each presentation.